Abstract: Nanoparticles comprise a drug, a first block polymer and a second block polymer. The first block polymer has a poly(ethylene oxide) (PEO) block and a polycarbonate block bearing a side chain aromatic nitrogen-containing heterocycle (N-heterocycle). The N-heterocycle can be in the form of a base, a hydrosalt of the base, a sulfobetaine adduct of the base, or a combination thereof. The second block polymer has a PEO block and a polycarbonate block bearing a side chain catechol group, which can be present as a catechol, oxidized form of a catechol, and/or a polymerized form of a catechol. The nanoparticles can be dispersed in water and are capable of controlled release of the drug.
Type:
Grant
Filed:
June 20, 2017
Date of Patent:
April 7, 2020
Assignees:
International Business Machines Corporation, Agency For Science, Technology And Research, Universidad del Pais Vasco/Euskal Herriko Unibersitatea
Inventors:
Julian M. W. Chan, Amanda C. Engler, James L. Hedrick, Haritz Sardon, Jeremy P. K. Tan, Yi Yan Yang
Abstract: Resorbable multifilament yarns and monofilament fibers including poly-4-hydroxybutyrate and copolymers thereof with high tenacity or high tensile strength have been developed. The yarns and fibers are produced by cold drawing the multifilament yarns and monofilament fibers before hot drawing the yarns and fibers under tension at temperatures above the melt temperature of the polymer or copolymer. These yarns and fibers have prolonged strength retention in vivo making them suitable for soft tissue repairs where high strength and strength retention is required. The multifilament yarns have tenacities higher than 8.1 grams per denier, and in vivo, retain at least 65% of their initial strength at 2 weeks. The monofilament fibers retain at least 50% of their initial strength at 4 weeks in vivo. The monofilament fibers have tensile strengths higher than 500 MPa. These yarns and fibers may be used to make various medical devices for various applications.
Type:
Grant
Filed:
March 19, 2018
Date of Patent:
March 17, 2020
Assignee:
Tepha, Inc.
Inventors:
Amit Ganatra, Fabio Felix, Bhavin Shah, Matthew Bernasconi, Said Rizk, David P. Martin, Simon F. Williams
Abstract: The present invention relates to the use of silver(I) monophosphine complexes as Active Pharmaceutical Ingredients (API's), including anticancer agents, for the treatment, diagnosis and/or prevention of cancer. The present invention also relates to pharmaceutical compositions containing such complexes and further extends to a method of treating or diagnosing a subject/patient suffering from cancer.
Abstract: A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer.
Type:
Grant
Filed:
December 18, 2018
Date of Patent:
February 18, 2020
Assignees:
Wayne State University, The United States of America as Represented by the Secretary, Department of Health and Human Service
Inventors:
Kannan Rangaramanujam, Sujatha Kannan, Roberto Romero, Raghavendra S Navath, Hui Dai, Anupa R. Menjoge
Abstract: The compositions and methods of the invention provide compositions and methods for preferential targeting of tissues to delivery therapeutic or diagnostic agents. For example, such compounds are useful in the treatment of joint disorders those affecting articulating joints, e.g., injury-induced osteoarthritis as well as autoimmune diseases affecting joint tissue such as rheumatoid arthritis.
Type:
Grant
Filed:
August 25, 2017
Date of Patent:
February 11, 2020
Assignee:
Rhode Island Hospital
Inventors:
Qian Chen, Yupeng Chen, Hongchuan Yu, Michael G. Ehrlich
Abstract: Compositions and methods for modified dendrimer nanoparticle (“MDNP”) delivery of therapeutic, prophylactic and/or diagnostic agent such as large repRNA molecules to the cells of a subject have been developed. MDNPs efficiently drive proliferation of antigen-specific T cells against intracellular antigen, and potentiate antigen-specific antibody responses. MDNPs can be multiplexed to deliver two or more different repRNAs to modify expression kinetics of encoded antigens and to simultaneous deliver repRNAs and mRNAs including the same UTR elements that promote expression of encoded antigens.
Type:
Grant
Filed:
September 23, 2016
Date of Patent:
February 4, 2020
Assignees:
Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research
Inventors:
Omar F. Khan, Jasdave S. Chahal, Daniel G. Anderson, Hidde Ploegh, Robert S. Langer, Tyler E. Jacks, David A. Canner
Abstract: In one aspect, methods of targeted nanoparticle and cell delivery are described herein. In some embodiments, methods described herein comprise coupling nanoparticles and cells to a carrier cell to form a nanoparticle-cell conjugate or cell-cell conjugate, disposing the nanoparticle-cell or cell-cell conjugate in a biological environment, and delivering the nanoparticles and cells to target cells or tissues located within the biological environment. The nanoparticles comprise a biodegradable photoluminescent polymer, and the nanoparticle-cell conjugate is formed using one or more click chemistry reaction products.
Abstract: Provided are aromatic compounds, phospholipid-polymer-aromatic conjugates comprising the aromatic compounds, and liposome compositions including the phospholipid-polymer-aromatic conjugates. The liposomal compositions may be useful for imaging of Alzheimer's Disease, for example, imaging of the amyloid-? plaque deposits characteristic of Alzheimer's Disease.
Type:
Grant
Filed:
December 1, 2016
Date of Patent:
January 21, 2020
Assignee:
TEXAS CHILDREN'S HOSPITAL
Inventors:
Ananth Annapragada, Eric A. Tanifum, Mayank Srivastava
Abstract: A synthetic calcium phosphate-based biomedical material comprising gadolinium. The material may comprises a compound having the general chemical formula: Ca10?yGdy(PO4)6?x(SiO4)x(OH)2?c+y where 0<x<1.3 and 0<y<1.3.
Type:
Grant
Filed:
January 27, 2017
Date of Patent:
January 14, 2020
Assignees:
ApaTech Limited, University Court of the University of Aberdeen
Inventors:
Iain Ronald Gibson, Janet Mabel Scott Skakle, Nigel Smith, Thomas Buckland
Abstract: The invention generally relates to materials and methods for creating and/or utilizing upconverting luminescence. More particularly, the invention relates to novel compositions (e.g., nanoparticles) and related methods of preparation and use that enable upconverting luminescence with an efficient excitation optimized at about 800 nm. A unique class of cascade sensitized tri-doped UCNPs with a biocompatiable 800 nm excitable property are disclosed herein, for example, tri-doped ?-NaYF4:Nd, Yb, Er (Tm)/NaYF4UCNPs, which employ Nd3+ as 800 nm photon sensitizer and Yb3+ as bridging ions, having strong green or blue upconversion emissions without photobleaching.
Abstract: A process for depositing an inorganic material on a substrate, the process comprising, providing a substrate having a surface, providing a precursor mixture comprising a metal sulfonate, and delivering the precursor mixture to the surface of the substrate, wherein the surface of the substrate is at a substrate temperature of above 450° C. and is sufficient to effect decomposition of the metal sulfonate. The inorganic material may include a metal or a metal oxide. The preferred metal sulfonate is metal triflate.
Type:
Grant
Filed:
February 10, 2016
Date of Patent:
December 24, 2019
Assignees:
Pilkington Group Limited, University College London
Inventors:
Deborah Raisbeck, Simon James Hurst, Ivan P. Parkin, Claire J. Carmalt, Joe A. Manzi
Abstract: Couplers for ultrasound probes can have a solid coupler body with a cavity having a malleable shape so as to be able to be conform to and/or self-attach to the end of the probe by a user pressing the coupler body against the ultrasound probe so that the coupler body takes on the underlying shape of the ultrasound probe while the exterior body can retain its pre-attached shape.
Abstract: A compound or a polymer is claimed. A first formula can be wherein X is H, CH3, CN, phenyl, substituted phenyl, (CH2)mZ, or phenyl(CH2)mZ; T is O, N, S or NH; m equals 1 to 20; n equals 1-100; and Z is CN, NH2, Thiol, OH, or CO2H. The second formula is: wherein X is H, CH3, CN, phenyl, substituted phenyl, (CH2)mZ, or phenyl(CH2)mZ; and Z is CN, NH2, Thiol, OH, or CO2H. The third formula is wherein: R1, R2, R3, and R4 are independently: H, CH3, OH, or a halogen.
Type:
Grant
Filed:
February 5, 2018
Date of Patent:
December 17, 2019
Assignee:
Bar-Ilan University
Inventors:
Shlomo Margel, Dana Mizrahi, Eran Gluz, Ravit Chen
Abstract: The invention generally relates to synthetic mimics of cell penetrating peptides. More particularly, the invention relates to certain novel monomers, oligomers and polymers (e.g., co-polymers) that are useful for the preparation of synthetic mimics of cell penetrating peptides, their compositions, preparations and use.
Type:
Grant
Filed:
October 23, 2018
Date of Patent:
December 3, 2019
Assignee:
University of Massachusetts
Inventors:
Gregory N. Tew, Gregory J. Gabriel, Abhigyan Som, Arife Ozgul Tezgel
Abstract: The present invention includes a novel method capable of identifying a compound as an imaging agent using a DAZAX-based scaffold or derivative thereof. The present invention further includes novel imaging agents. The present invention further includes a method of modifying a DAZAX-based scaffold or derivative thereof. The present invention further includes a method for imaging a sample.
Type:
Grant
Filed:
March 20, 2015
Date of Patent:
November 26, 2019
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Inventors:
David M. Chenoweth, Robert-Andre F. Rarig, Mai N. Tran
Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Type:
Grant
Filed:
July 14, 2016
Date of Patent:
November 26, 2019
Assignee:
Vifor (International) Ltd.
Inventors:
Dominique Charmot, Han-Ting Chang, Gerrit Klaerner, Jerry M. Buysse, Mingjun Liu
Abstract: Described herein are nanoparticle drug conjugates (NDCs), which, in certain embodiments, comprise a non-toxic, multi-modality, clinically proven silica-based nanoparticle platform with covalently attached drug molecules/moieties. The nanoparticle drug conjugates (NDCs) demonstrate imaging capability and targeting ligands which efficiently clear through the kidneys. Furthermore, the conjugates incorporate therapeutic agents for cancer detection, prevention, and/or treatment.
Type:
Grant
Filed:
September 21, 2018
Date of Patent:
November 26, 2019
Assignees:
Memorial Sloan Kettering Cancer Center, Cornell University
Inventors:
Michelle S. Bradbury, Barney Yoo, Ulrich Wiesner, Kai Ma
Abstract: Described herein are polymeric drug-carrying nanogels that are capable of targeting to P-selectin for the treatment of cancer and other diseases and conditions associated with P-selectin. Furthermore, in certain embodiments, the nanogels presented here offer a drug release mechanism based on acidic pH in the microenvironment of a tumor, thereby providing improved treatment targeting capability and allowing use of lower drug doses, thereby reducing toxicity.
Type:
Grant
Filed:
January 7, 2019
Date of Patent:
November 19, 2019
Assignee:
Memorial Sloan Kettering Cancer Center
Inventors:
Adriana Haimovitz-Friedman, Daniel A. Heller, Yosef Shamay
Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
Type:
Grant
Filed:
October 3, 2017
Date of Patent:
November 5, 2019
Assignee:
Nektar Therapeutics
Inventors:
Xuan Zhao, Michael D. Bentley, Zhongxu Ren, Tacey X. Viegas
Abstract: The present invention relates to a nanoparticle composition which is prepared by a process which is characterized by dissolving a poorly water-soluble compound or the like under a high temperature and a high pressure, and milling a suspension or the like containing a uniform crystal obtained by cooling the obtained solution.